Brokerages Set Natera, Inc. (NASDAQ:NTRA) Target Price at $184.63

Shares of Natera, Inc. (NASDAQ:NTRA - Get Free Report) have been given an average recommendation of "Buy" by the fifteen brokerages that are presently covering the company, MarketBeat.com reports. Fifteen equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $184.63.

A number of equities analysts recently commented on NTRA shares. Piper Sandler lifted their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Morgan Stanley boosted their price target on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Barclays lifted their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, UBS Group upped their price target on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $7.71 during mid-day trading on Friday, reaching $164.16. 2,467,932 shares of the company's stock were exchanged, compared to its average volume of 1,412,867. Natera has a twelve month low of $92.14 and a twelve month high of $183.00. The firm has a market capitalization of $22.42 billion, a price-to-earnings ratio of -111.67 and a beta of 1.74. The business's fifty day moving average price is $157.84 and its 200-day moving average price is $158.54.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same period in the previous year, the business earned ($0.56) EPS. The business's quarterly revenue was up 36.5% compared to the same quarter last year. Analysts predict that Natera will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 9,563 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the transaction, the chief executive officer now directly owns 212,541 shares of the company's stock, valued at $29,417,799.81. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the sale, the insider now directly owns 141,782 shares of the company's stock, valued at approximately $19,917,535.36. The trade was a 2.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,755 shares of company stock valued at $8,898,589 in the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. LRI Investments LLC bought a new stake in shares of Natera during the fourth quarter worth about $29,000. Bank of Jackson Hole Trust acquired a new position in Natera during the 1st quarter valued at about $29,000. Rakuten Securities Inc. increased its holdings in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares in the last quarter. ORG Partners LLC purchased a new stake in shares of Natera in the first quarter worth approximately $32,000. Finally, TCTC Holdings LLC lifted its holdings in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.